BioRestorative (BRTX) Completes Phase 2 Dosing of BRTX-100; Data Expected in 2027

BioRestorative Therapies (NASDAQ: BRTX) said on May 26, 2026 it has completed dosing in its Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease, a key step enabling the spinal cell therapy program to move toward a data readout in 2027. No safety issues were flagged during the enrollment, the company stated. BRTX-100 is an autologous stem cell-based treatment designed to address degenerative disc conditions with a single injection. The blinded, controlled study will now follow participants for efficacy endpoints. Management indicated that the completion of dosing keeps the timeline on track for top-line results next year. BioRestorative is also developing a metabolic program, ThermoStem, targeting obesity.